Addition of Ceftaroline to Daptomycin after Emergence of Daptomycin-Nonsusceptible Staphylococcus aureus during Therapy Improves Antibacterial Activity.

Pharmacy Practice Division, University of Wisconsin-Madison School of Pharmacy.
Antimicrobial Agents and Chemotherapy (Impact Factor: 4.57). 08/2012; 56(10):5296-302. DOI: 10.1128/AAC.00797-12
Source: PubMed

ABSTRACT Antistaphylococcal beta-lactams enhance daptomycin activity and have been used successfully in combination for refractory methicillin-resistant Staphylococcus aureus (MRSA) infections. Ceftaroline possesses MRSA activity, but it is unknown if it improves the daptomycin potency comparably to other beta-lactams. We report a complex patient case of endocarditis who was treated with daptomycin in combination with ceftaroline, which resulted in clearance of a daptomycin-nonsusceptible strain. An in vitro pharmacokinetic/pharmacodynamic model of renal failure was used to simulate the development of daptomycin resistance and evaluate the microbiologic effects of daptomycin plus ceftaroline treatment. Combination therapy with daptomycin and ceftaroline restored daptomycin sensitivity in vivo and resulted in clearance of persistent blood cultures. Daptomycin susceptibility in vitro was increased in the presence of either ceftaroline or oxacillin. Daptomycin at 6 mg/kg of body weight every 48 h was bactericidal in the model but resulted in regrowth and daptomycin resistance (MIC, 2 to 4 μg/ml) with continued monotherapy. The addition of ceftaroline at 200 mg every 12 h after the emergence of daptomycin resistance enhanced bacterial killing. Importantly, daptomycin plus ceftaroline as the initial combination therapy produced rapid and sustained bactericidal activity and prevented daptomycin resistance. Both in vivo- and in vitro-derived daptomycin resistance resulted in bacteria with more fluid cell membranes. After ceftaroline was added in the model, fluidity was restored to the level of the initial in vivo isolate. Daptomycin-resistant isolates required high daptomycin exposures (at least 10 mg/kg) to optimize cell membrane damage with daptomycin alone. Ceftaroline combined with daptomycin was effective in eliminating daptomycin-resistant MRSA, and these results further justify the potential use of daptomycin plus beta-lactam therapy for these refractory infections.

1 Bookmark
  • [Show abstract] [Hide abstract]
    ABSTRACT: Methicillin-resistant Staphylococcus aureus (MRSA) has emerged as one of the most important nosocomial pathogens. Resistance to antibiotic therapy has been known to emerge especially in clinically complex scenarios, resulting in challenges in determining optimal treatment of serious MRSA. Daptomycin, in combination with other antibiotics, has been successfully used in the treatment of these infections, with the aims of resulting in reducing the prevention of antimicrobial resistance and increased killing compared with daptomycin monotherapy. This article reviews all the published studies that used daptomycin combination therapy for the treatment of bacteremia and associated complicated infections caused by gram-positive organisms, including MRSA. We discuss the rationale of combination antibiotics and the mechanisms that enhance the activity of daptomycin, with special focus on the role of β-lactam antibiotics. There are limited clinical data on the use of daptomycin in combination with other antibiotics. Most of this use was as successful salvage therapy in the setting of failing primary, secondary, or tertiary therapy and/or relapsing infection. Synergy between β-lactams and daptomycin is associated with several characteristics, including increased daptomycin binding and β-lactam-mediated potentiation of innate immunity, but the precise molecular mechanism is unknown. Use of daptomycin in combination with other antibiotics, especially β-lactams, offers a promising treatment option for complicated MRSA bacteremia in which emergence of resistance during treatment may be anticipated. Because it is currently not possible to differentiate complicated from uncomplicated bacteremia at the time of presentation, combination therapy may be considered as first-line therapy, with de-escalation to monotherapy in uncomplicated cases and cases with stable pharmacologic and surgical source control. Copyright © 2014 Elsevier HS Journals, Inc. All rights reserved.
    Clinical Therapeutics 10/2014; 36(10):1303-1316. DOI:10.1016/j.clinthera.2014.09.005 · 2.59 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Ceftaroline (CPT), the active metabolite of the prodrug ceftaroline-fosamil (CPT-F) demonstrates in vitro bactericidal activity against methicillin-resistant Staphylococcus aureus (MRSA) and is effective in difficult-to-treat MRSA endocarditis and acute osteomyelitis rabbit models. However, its in vivo efficacy in a prosthetic joint infection (PJI) model is unknown. Using an MRSA knee PJI in rabbits, the efficacies of CPT-F or vancomycin (VAN) alone or combined with rifampin (RIF) were compared. After partial knee replacement with a silicone implant fitting into the tibial intramedullary canal, 5 × 10(7) MRSA CFU (MICs 0.38, 0.006 and 1 mg/liter for CPT, RIF and VAN, respectively) were injected into the knees. Infected animals were randomly assigned to receive no treatment (controls) or CPT-F (60 mg/kg i.m.), VAN (60 mg/kg i.m.), CPT-F+RIF (10 mg/kg i.m.) or VAN+RIF starting 7 days post-inoculation and lasting 7 days. Surviving bacteria in crushed tibias were counted 3 days after ending treatment. Although in vivo mean log10 CFU/g of CPT- (3.0 ± 0.9, n = 12) or VAN-treated crushed bones (3.5 ± 1.1, n = 12) were significantly lower than controls (5.6 ± 1.1, n = 14) (P < 0.001), neither fully sterilized bones (3/12 for each). Means (log10 CFU/g) in combination with RIF were 1.9 ± 0.5 (12/14 sterile) for CPT-F and 1.9 ± 0.5 (12/14 sterile) for VAN. In this MRSA-PJI model, CPT-F and VAN efficacies did not differ, and ceftaroline appears to be a promising antimicrobial agent for the treatment of MRSA PJIs.
    Antimicrobial Agents and Chemotherapy 08/2014; 58(11). DOI:10.1128/AAC.03600-14 · 4.45 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Gram-positive bacteria to include methicillin-resistant Staphylococcus aureus (MRSA), methicillin-susceptible Staphylococcus aureus (MSSA), and enterococci, to include vancomycin-resistant enterococci (VRE), display a remarkable array of resistance and virulence factors, which have contributed to their prominent role in infections of the critically ill. Over the last three decades infections with these pathogens has increased as has their overall resistance to available antimicrobial agents. This has led to the development of a number of new antibiotics for the treatment of Gram-positive bacteria. At present, it is important that clinicians recognize the changing resistance patterns and epidemiology of Gram-positive bacteria as these factors may impact patient outcomes. The increasing range of these pathogens, such as the emergence of community-associated MRSA clones, emphasizes that all specialties of physicians treating infections should have a good understanding of the infections caused by Gram-positive bacteria in their area of practice. When initiating empiric antibiotics, it is of vital importance that this therapy be timely and appropriate, as delays in treatment are associated with adverse outcomes. Although vancomycin has traditionally been considered a first-line therapy for serious MRSA infections, multiple concerns with this agent have opened the door for alternative agents demonstrating efficacy in this role. Similarly, the expansion of VRE as a pathogen in the ICU setting has required the development of agents targeting this important pathogen.
    BMC Infectious Diseases 01/2014; 14(1):92. DOI:10.1186/1471-2334-14-92 · 2.56 Impact Factor


Available from
May 22, 2014